Premium
1 Yeast‐based fermentate supplementation significantly reduces inflammation in two separate in vivo models
Author(s) -
Robinson Larry E,
Evans Malkanthi,
Reeves Stuart G,
Guthrie Najla,
Moyad Mark A
Publication year - 2011
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.25.1_supplement.785.1
OBJECTIVES A total of 3 published double‐blind, placebo‐controlled, randomized trials of a yeast‐based fermentate of Saccharomyces cerevisiae have demonstrated a consistent ability to function as an immune modulating agent by significantly reducing cold/flu‐like and allergic rhinitis symptoms. METHODS A systemic model of systemic and localized in vivo inflammation was utilized. DBA/1J mice were immunized with type II collagen and treated with the intervention or control over 4 week period as an autoimmune model. Sprague Dawley rats were given daily intervention or control for 2 weeks and subsequently injected with carrageenan as model of localized edema. RESULTS Treated mice experienced significantly lower arthritis scores, reduced antibody response to type II collagen, and lower interferon‐gamma levels (all p<0.05). Treated rats experienced reduced swelling, prostaglandin E2, and nerve growth factor (all p<0.05). CONCLUSIONS In medically established in vivo models of systemic and localized inflammation, this yeast‐based fermentate product offers a potential therapeutic option that should be tested in a clinical setting. Source of Funding: Embria Health Sciences